148 related articles for article (PubMed ID: 37081722)
1. Pyrotinib alone or in combination with docetaxel in refractory HER2-positive gastric cancer: A dose-escalation phase I study.
Liu D; Kou F; Gong J; Wang Z; Zhang X; Li J; Li Y; Li J; Zhou J; Lu M; Wang X; Lu Z; Cao Y; Zou J; Zhu X; Xu R; Shen L
Cancer Med; 2023 May; 12(9):10704-10714. PubMed ID: 37081722
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial.
Wu J; Jiang Z; Liu Z; Yang B; Yang H; Tang J; Wang K; Liu Y; Wang H; Fu P; Zhang S; Liu Q; Wang S; Huang J; Wang C; Wang S; Wang Y; Zhen L; Zhu X; Wu F; Lin X; Zou J
BMC Med; 2022 Dec; 20(1):498. PubMed ID: 36575513
[TBL] [Abstract][Full Text] [Related]
3. Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
Ma F; Li Q; Chen S; Zhu W; Fan Y; Wang J; Luo Y; Xing P; Lan B; Li M; Yi Z; Cai R; Yuan P; Zhang P; Li Q; Xu B
J Clin Oncol; 2017 Sep; 35(27):3105-3112. PubMed ID: 28498781
[TBL] [Abstract][Full Text] [Related]
4. Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial.
Ma F; Yan M; Li W; Ouyang Q; Tong Z; Teng Y; Wang Y; Wang S; Geng C; Luo T; Zhong J; Zhang Q; Liu Q; Zeng X; Sun T; Mo Q; Liu H; Cheng Y; Cheng J; Wang X; Nie J; Yang J; Wu X; Wang X; Li H; Ye C; Dong F; Wu S; Zhu X; Xu B;
BMJ; 2023 Oct; 383():e076065. PubMed ID: 37907210
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant Pyrotinib plus Trastuzumab, Docetaxel, and Carboplatin in Early or Locally Advanced Human Epidermal Receptor 2-Positive Breast Cancer in China: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.
Ding Y; Mo W; Xie X; Wang O; He X; Zhao S; Gu X; Liang C; Qin C; Ding K; Yang H; Ding X
Oncol Res Treat; 2023; 46(7-8):303-311. PubMed ID: 37302393
[TBL] [Abstract][Full Text] [Related]
6. Multicenter phase I dose escalation and expansion study of pyrotinib in combination with camrelizumab and chemotherapy as first-line treatment for HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma.
Li S; Bao J; Li X; Yang Q; Xu J; Chen S; Feng G; Gao C; Feng L; Lu B; Miao M; Ni X; Wang G; Yang L; Zhu L
EClinicalMedicine; 2023 Dec; 66():102314. PubMed ID: 38024480
[TBL] [Abstract][Full Text] [Related]
7. Pyrotinib plus docetaxel as first-line treatment for HER2-positive metastatic breast cancer: the PANDORA phase II trial.
Zheng Y; Cao WM; Shao X; Shi Y; Cai L; Chen W; Liu J; Shen P; Chen Y; Wang X; Li H; Li M; Chen Z; Wang X
Nat Commun; 2023 Dec; 14(1):8314. PubMed ID: 38097605
[TBL] [Abstract][Full Text] [Related]
8. Pyrotinib or Lapatinib Combined With Capecitabine in HER2-Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study.
Ma F; Ouyang Q; Li W; Jiang Z; Tong Z; Liu Y; Li H; Yu S; Feng J; Wang S; Hu X; Zou J; Zhu X; Xu B
J Clin Oncol; 2019 Oct; 37(29):2610-2619. PubMed ID: 31430226
[TBL] [Abstract][Full Text] [Related]
9. Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial.
Pernas S; Martin M; Kaufman PA; Gil-Martin M; Gomez Pardo P; Lopez-Tarruella S; Manso L; Ciruelos E; Perez-Fidalgo JA; Hernando C; Ademuyiwa FO; Weilbaecher K; Mayer I; Pluard TJ; Martinez Garcia M; Vahdat L; Perez-Garcia J; Wach A; Barker D; Fung S; Romagnoli B; Cortes J
Lancet Oncol; 2018 Jun; 19(6):812-824. PubMed ID: 29706375
[TBL] [Abstract][Full Text] [Related]
10. Rationale and design of a phase II trial of pyrotinib in combination with nab-paclitaxel as adjuvant therapy for N0/N1mi, HER2 + early breast cancer (PHAEDRA).
Wang C; Zhou Y; Lin Y; Mao F; Guan J; Zhang X; Shen S; Wang X; Zhang Y; Pan B; Zhong Y; Peng L; Cao X; Yao R; Zhou X; Xu C; Xu Y; Sun Q
BMC Cancer; 2022 Mar; 22(1):269. PubMed ID: 35287613
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant Pyrotinib plus Trastuzumab and Chemotherapy for Stage I-III HER2-Positive Breast Cancer: A Phase II Clinical Trial.
Xuhong J; Qi X; Tang P; Fan L; Chen L; Zhang F; Tan X; Yan W; Zhong L; He C; Liang Y; Ren L; Wang M; Zhang Y; Jiang J
Oncologist; 2020 Dec; 25(12):e1909-e1920. PubMed ID: 33000490
[TBL] [Abstract][Full Text] [Related]
12. Pyrotinib in combination with letrozole for hormone receptor-positive, human epidermal growth factor receptor 2-positive metastatic breast cancer (PLEHERM): a multicenter, single-arm, phase II trial.
Hu ZY; Yan M; Xiong H; Ran L; Zhong J; Luo T; Sun T; Xie N; Liu L; Yang X; Xiao H; Li J; Liu B; Ouyang Q
BMC Med; 2023 Jun; 21(1):226. PubMed ID: 37365596
[TBL] [Abstract][Full Text] [Related]
13. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial.
Xu B; Yan M; Ma F; Hu X; Feng J; Ouyang Q; Tong Z; Li H; Zhang Q; Sun T; Wang X; Yin Y; Cheng Y; Li W; Gu Y; Chen Q; Liu J; Cheng J; Geng C; Qin S; Wang S; Lu J; Shen K; Liu Q; Wang X; Wang H; Luo T; Yang J; Wu Y; Yu Z; Zhu X; Chen C; Zou J;
Lancet Oncol; 2021 Mar; 22(3):351-360. PubMed ID: 33581774
[TBL] [Abstract][Full Text] [Related]
14. [Efficacy and safety of oral pyrotinib in HER2 positive metastatic breast cancer: real-world practice].
Song GH; Li HP; DI LJ; Yan Y; Jiang HF; Xu L; Wan DG; Li Y; Wang MP; Xiao Y; Zhang RY; Ran R; Wang H
Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Apr; 52(2):254-260. PubMed ID: 32306007
[TBL] [Abstract][Full Text] [Related]
15. Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial.
Li Q; Guan X; Chen S; Yi Z; Lan B; Xing P; Fan Y; Wang J; Luo Y; Yuan P; Cai R; Zhang P; Li Q; Zhong D; Zhang Y; Zou J; Zhu X; Ma F; Xu B
Clin Cancer Res; 2019 Sep; 25(17):5212-5220. PubMed ID: 31138588
[TBL] [Abstract][Full Text] [Related]
16. A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer.
Jhaveri K; Wang R; Teplinsky E; Chandarlapaty S; Solit D; Cadoo K; Speyer J; D'Andrea G; Adams S; Patil S; Haque S; O'Neill T; Friedman K; Esteva FJ; Hudis C; Modi S
Breast Cancer Res; 2017 Aug; 19(1):89. PubMed ID: 28764748
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of pyrotinib-containing regimen in the patients with HER2-positive metastatic breast cancer: A multicenter real-world study.
Yin S; Chi Y; Du Y; Wang J; Shan C; Yi W; Shang M; Man X; Tan Q; Li H
Cancer Med; 2023 Feb; 12(3):2333-2344. PubMed ID: 35894763
[TBL] [Abstract][Full Text] [Related]
19. Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial.
Yan M; Ouyang Q; Sun T; Niu L; Yang J; Li L; Song Y; Hao C; Chen Z; Orlandi A; Ishii N; Takabe K; Franceschini G; Ricci F; Verschraegen C; Liu Z; Zhang M; Lv H; Liu L; Yang X; Xiao H; Gao Z; Li X; Dong F; Chen X; Qiao J; Zhang G
Lancet Oncol; 2022 Mar; 23(3):353-361. PubMed ID: 35085506
[TBL] [Abstract][Full Text] [Related]
20. Pathological response and predictive role of tumour-infiltrating lymphocytes in HER2-positive early breast cancer treated with neoadjuvant pyrotinib plus trastuzumab and chemotherapy (Panphila): a multicentre phase 2 trial.
Liu Z; Wang C; Chen X; Zhu J; Sun X; Xia Q; Lu Z; Qiao J; Zhou Y; Wang H; Wang Y; Yan M
Eur J Cancer; 2022 Apr; 165():157-168. PubMed ID: 35235873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
